Very early researchUnknownNCT04637269What this trial is testingAnti-BCMA CAR-T Cell Therapy for the R/R Multiple MyelomaWho this might be right forMultiple Myeloma Xinqiao Hospital of Chongqing 16
Early research (Phase 1)Ended earlyNCT03465540What this trial is testingSafety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesWho this might be right forMultiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more Amgen 24
Testing effectiveness (Phase 2)Study completedNCT03170882What this trial is testingIxazomib, Given With Dexamethasone in Adults With Multiple MyelomaWho this might be right forRelapsed and/or Refractory Multiple Myeloma Millennium Pharmaceuticals, Inc. 122
Testing effectiveness (Phase 2)Looking for participantsNCT06988488What this trial is testingDetermine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Celgene 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT04094961What this trial is testingIxazomib + Pomalidomide + Dexamethasone In MMWho this might be right forMultiple MyelomaMultiple Myeloma in Relapse Omar Nadeem, MD 52
Early research (Phase 1)Not Yet RecruitingNCT07407010What this trial is testingBCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMWho this might be right forRelapsed Refractory Multiple Myeloma (RRMM) Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)UnknownNCT03767751What this trial is testingA Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Chinese PLA General Hospital 80
Testing effectiveness (Phase 2)UnknownNCT01522872What this trial is testingOpen-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Threshold Pharmaceuticals 98
Testing effectiveness (Phase 2)Study completedNCT02056756What this trial is testingCarfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple MyelomaWho this might be right forMultiple Myeloma Stichting European Myeloma Network 63
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142What this trial is testingCombination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaWho this might be right forMultiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM) National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Ended earlyNCT01670994What this trial is testingQUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Altor BioScience 6
Large-scale testing (Phase 3)Study completedNCT00799461What this trial is testingInternet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+89 more Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium 1,337
Large-scale testing (Phase 3)Study completedNCT01324947What this trial is testingStudy to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Celgene 74
Large-scale testing (Phase 3)Study completedNCT02990338What this trial is testingMultinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsWho this might be right forPlasma Cell Myeloma Sanofi 307
Testing effectiveness (Phase 2)Study completedNCT00253578What this trial is testingSorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRefractory Multiple Myeloma National Cancer Institute (NCI) 40
Early research (Phase 1)Ended earlyNCT03379584What this trial is testingA Safety Study of SGN-CD48A in Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Seagen Inc. 14
Not applicableStudy completedNCT05887206What this trial is testingCorneal Toxicity in Patients Treated by Belantamab MafodotinWho this might be right forMyeloma Multiple Centre Hospitalier Universitaire de Saint Etienne 43
Testing effectiveness (Phase 2)Study completedNCT01775553What this trial is testingStudy of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose CarfilzomibWho this might be right forRelapse Multiple MyelomaRefractory Multiple Myeloma Ajai Chari 13
Testing effectiveness (Phase 2)UnknownNCT02248402What this trial is testingAutologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Chonnam National University Hospital 15
Very early researchUnknownNCT04626752What this trial is testingCAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Hebei Senlang Biotechnology Inc., Ltd. 50